

Current Opinions and Modern Approaches in the Diagnosis and Treatment of DRY EYE DISEASE

VISIT [HTTP://WWW.TINYURL.COM/CURRENTOPINIONSDRYEYE](http://www.tinyurl.com/currentopinionsdryeye) FOR ONLINE TESTING AND INSTANT CME CERTIFICATE.

FACULTY

KENNETH A. BECKMAN, MD

(Chair and Moderator)

JODI LUCHS, MD

CYNTHIA MATOSSIAN, MD, FACS, ABES

MARGUERITE B. MCDONALD, MD, FACS

MARK S. MILNER, MD, FACS

TERRENCE P. O'BRIEN, MD

HELEN K. WU, MD

ORIGINAL RELEASE: **JULY 1, 2017**

EXPIRATION: **JULY 31, 2018**



LEARNING METHOD AND MEDIUM

This educational activity consists of a supplement and ten (10) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 2.0 hours to complete.

CONTENT SOURCE

This continuing medical education (CME) activity captures content from an expert roundtable discussion held on January 17, 2017, in Koloa, Hawaii.

ACTIVITY DESCRIPTION

Population studies have estimated the prevalence of dry eye disease (DED) in the United States to range between 5% and 35%, depending on the severity of symptoms. Understanding of the pathophysiology has provided a foundation for developments in diagnostic modalities and therapies. The purpose of this activity is to update ophthalmologists on the role of inflammation in the pathophysiology of DED and new diagnosis and new treatment options.

TARGET AUDIENCE

This educational activity is intended for ophthalmologists.

LEARNING OBJECTIVES

Upon completion of this activity, ophthalmologists will be better able to:

- Diagnose dry eye disease using at least 1 objective test, regardless of symptom severity
- Describe the implications of inflammation in dry eye disease on diagnosis and treatment approaches
- Describe clinically relevant results from clinical trials assessing anti-inflammatory drugs for the treatment of DED
- Select appropriate DED treatment based on individual patient characteristics and an appropriate approach

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of **New York Eye and Ear Infirmary of Mount Sinai** and MedEdicus LLC. The **New York Eye and Ear Infirmary of Mount Sinai** is accredited by the ACCME to provide continuing medical education for physicians.



In July 2013, the Accreditation Council for Continuing Medical Education (ACCME) awarded New York Eye and Ear Infirmary of Mount Sinai "Accreditation with Commendation," for six years as a provider of continuing medical education for physicians, the highest accreditation status awarded by the ACCME.

AMA CREDIT DESIGNATION STATEMENT

The **New York Eye and Ear Infirmary of Mount Sinai** designates this enduring material for a maximum of 2.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GRANTOR STATEMENT

This continuing medical education activity is supported through an unrestricted educational grant from Shire.

DISCLOSURE POLICY STATEMENT

It is the policy of **New York Eye and Ear Infirmary of Mount Sinai** that the faculty and anyone in a position to control activity content disclose any real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). **New York Eye and Ear Infirmary of Mount Sinai** has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Full disclosure of faculty/planners and their commercial relationships, if any, follows.

DISCLOSURES

Kenneth A. Beckman, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Royalty*: Holbar Medical, Inc; *Consultant/Advisory Board*: Alcon; Allergan; Bausch & Lomb Incorporated; Omeros Corporation; Shire; Sun; and TearLab Corporation; *Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus)*: Alcon; Allergan; Shire; and TearLab Corporation; *Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds)*: Rapid Pathogen Screening, Inc.

Jodi Luchs, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Alcon; Allergan; Bausch & Lomb Incorporated; Ocular Science; Shire; and TearLab Corporation; *Contracted Research*: Alcon; Allergan; Bausch & Lomb Incorporated; and Shire; *Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus)*: Allergan; Bausch & Lomb Incorporated; Shire; and TearLab Corporation; *Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds)*: Calhoun Vision, Inc; CXL Ophthalmics; Insightful Solutions, LLC; Omega Ophthalmics; Rapid Pathogen Screening, Inc; and Trefoil Therapeutics, LLC.

Cynthia Matossian, MD, FACS, ABES, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Abbott Medical Optics; Alcon; Allergan; Bausch & Lomb Incorporated; Marco; PRN; Shire; Sun Pharmaceutical Industries Ltd; TearLab Corporation; and TearScience; *Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus)*: Abbott Medical Optics; Alcon; Allergan; Bausch & Lomb Incorporated; Ocular Therapeutix, Inc; PRN; Shire; Sun Pharmaceutical Industries Ltd; TearLab Corporation; and TearScience; *Contracted Research*: Abbott Medical Optics; Glaukos Corporation; Icon Bioscience, Inc; iOptics; Ocular Therapeutix, Inc; PRN; Shire; Softec; and TearLab Corporation; *Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds)*: CheckedUp; Imprimis Pharmaceuticals, Inc; Ocular Therapeutix, Inc; PRN; Rapid Pathogen Screening, Inc; Strathspay Crown LLC (Alphaeon Corporation); and TearLab Corporation.

Marguerite B. McDonald, MD, FACS, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Abbott Medical Optics; Alcon Laboratories; Allergan; Altaire; Bausch & Lomb Incorporated; Bio-Tissue; BiphEx; CenterVue SpA; FOCUS Laboratories; NDC; Oculus USA; OCUSOFT; Optical Express; Orca Surgical; Perrigo Company plc; Rapid Pathogen Screening, Inc; Shire; TearLab Corporation; and TearScience. She reports Spouse financial agreements or affiliations as follows: *Consultant/Advisory Board*: Alcon Laboratories; CenterVue SpA; Oculus USA; and Optical Express.

Mark S. Milner, MD, FACS, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Allergan; Bausch & Lomb Incorporated; Shire; Sun Pharmaceutical Industries Ltd; and TearScience; *Contracted Research*: Eleven Biotherapeutics; Eyegate; and Kala Pharmaceuticals; *Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus)*: Allergan; Bausch & Lomb Incorporated; Shire; Sun Pharmaceutical Industries Ltd; and TearScience; *Ownership Interest (Stock options, or other holdings, excluding diversified mutual funds)*: Rapid Pathogen Screening, Inc.

Terrence P. O'Brien, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Alcon; Allergan; Bausch & Lomb Incorporated; Senju Pharmaceutical Co, Ltd; and Shire.

Helen K. Wu, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Allergan; *Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus)*: Shire.

NEW YORK EYE AND EAR INFIRMARY OF MOUNT SINAI PEER REVIEW DISCLOSURE

Priti Batta, MD, has no relevant commercial relationships to disclose.

EDITORIAL SUPPORT DISCLOSURES

Tony Realini, MD, MPH, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Alcon; Bausch & Lomb Incorporated; Inotek Pharmaceuticals Corporation; and Smith & Nephew; *Contracted Research*: Alcon; and F. Hoffmann-La Roche Ltd.

Diane McArdle, PhD; Cynthia Tornallyay, RD, MBA, CHCP; Kimberly Corbin, CHCP; Barbara Auel; and Barbara Lyon have no relevant commercial relationships to disclose.

DISCLOSURE ATTESTATION

The contributing physicians listed above have attested to the following:

- 1) that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- 2) that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- 3) that all reasonable clinical alternatives will be discussed when making practice recommendations.

OFF-LABEL DISCUSSION

This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

LAST REVIEW: May 24, 2017

For Digital Editions

System Requirements:

If you are viewing this activity online, please ensure the computer you are using meets the following requirements:

- **Operating System:** Windows or Macintosh
- **Media Viewing Requirements:** Flash Player or Adobe Reader
- **Supported Browsers:** Microsoft Internet Explorer, Firefox, Google Chrome, Safari, and Opera
- **A good Internet connection**

New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies

<http://www.nyee.edu/health-professionals/cme/enduring-activities>

CME PROVIDER CONTACT INFORMATION

For questions about this activity, call 212-979-4383.

TO OBTAIN AMA PRA CATEGORY 1 CREDIT[™]

To obtain *AMA PRA Category 1 Credit*[™] for this activity, read the material in its entirety and consult referenced sources as necessary. Complete the evaluation form along with the post test answer box within this supplement. Remove the Activity Evaluation/Credit Request page from the printed supplement or print the Activity Evaluation/Credit Request page from the Digital Edition. Scan and return via e-mail to cme@nyee.edu or fax to (212) 353-5703. Your certificate will be sent to the e-mail address you provide on the Activity Evaluation/Credit Request form. Please allow 3 weeks for Activity Evaluation/Credit Request forms to be processed. There are no fees for participating in and receiving CME credit for this activity.

Alternatively, we offer instant certificate processing and support Green CME. Please take this post test and evaluation online by going to <http://www.tinyurl.com/CurrentOpinionsDryEye>. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of **New York Eye and Ear Infirmary of Mount Sinai**, MedEdicus LLC, Shire, *EyeNet*, or American Academy of Ophthalmology.

This CME activity is copyrighted to MedEdicus LLC ©2017. All rights reserved.

PROGRAM CHAIR AND MODERATOR

KENNETH A. BECKMAN, MD

Clinical Assistant Professor of Ophthalmology
Ohio State University
Columbus, Ohio
Director of Corneal Surgery
Comprehensive Eye Care of Central Ohio
Westerville, Ohio

FACULTY

JODI LUCHS, MD

Associate Clinical Professor of Ophthalmology
Hofstra Northwell School of Medicine
Hempstead, New York
Director, Cornea/External Diseases
Director, Clinical Research
South Shore Eye Care
Wantagh, New York

CYNTHIA MATOSSIAN, MD, FACS, ABES

Clinical Assistant Professor of Ophthalmology (Adjunct)
Temple University School of Medicine
Philadelphia, Pennsylvania
Clinical Instructor
Department of Family Medicine
University of Medicine & Dentistry of New Jersey
Newark, New Jersey
Robert Wood Johnson Medical School
New Brunswick, New Jersey
Medical Director and CEO
Matossian Eye Associates
Doylestown, Pennsylvania
Hopewell, New Jersey

MARGUERITE B. MCDONALD, MD, FACS

Clinical Professor of Ophthalmology
NYU Langone Medical Center
New York, New York
Clinical Professor of Ophthalmology
Tulane University Health Sciences Center
New Orleans, Louisiana
Ophthalmic Consultants of Long Island
Lynbrook, New York

MARK S. MILNER, MD, FACS

Associate Clinical Professor
Department of Ophthalmology
Yale University School of Medicine
New Haven, Connecticut
Partner
The Eye Center of Southern Connecticut
Hamden, Connecticut

TERRENCE P. O'BRIEN, MD

Professor of Ophthalmology
Charlotte Breyer Rodgers Distinguished Chair in Ophthalmology
Director, Refractive Surgery Service
Bascom Palmer Eye Institute at Palm Beach Gardens
University of Miami Miller School of Medicine
Palm Beach Gardens, Florida

HELEN K. WU, MD

Assistant Professor of Ophthalmology
Tufts University School of Medicine
Director of Refractive Surgery
New England Eye Center
Boston, Massachusetts

CME REVIEWER FOR
NEW YORK EYE AND EAR INFIRMARY OF MOUNT SINAI

PRITI BATTA, MD

Assistant Professor of Ophthalmology
Icahn School of Medicine at Mount Sinai
Director, Medical Student Education
Assistant Director, Comprehensive Ophthalmology Service
New York Eye and Ear Infirmary of Mount Sinai
New York, New York

Current Opinions and Modern Approaches in the Diagnosis and Treatment of DRY EYE DISEASE

Introduction

The prevalence of dry eye disease (DED) is on the rise. This is due to many factors, including better diagnostics, greater awareness of the disease and its effect on our patients' quality of life, and the modern lifestyle that includes far greater time spent staring at device screens than ever before. New diagnostic and therapeutic tools assist us in dealing with this large and growing problem. In this educational activity, we will provide an update on the pathophysiology of DED, review our current array of tests, discuss new therapies for our patients with DED, and present a series of case studies to illustrate our approach to DED in 2017.

—Kenneth A. Beckman, MD

Epidemiology

Population studies have estimated the prevalence of DED in the United States to range between 5% and 35%, depending on the severity of symptoms. Studies evaluating severe DED symptoms report prevalence in the range of 4.3% to 7.8%^{1,2} for men and women aged 49 years and older, whereas studies with less strict case definitions report values in the range of 14.4% to 14.6% in US adults.^{3,4} Numerous risk factors for DED are known (**Table 1**).⁵ Of these, the most common are aging and female sex. Several aging changes predispose to DED, including a general reduction in corneal sensation leading to decreased blink rate and tear film instability, as well as a reduction in androgen hormones. The latter is particularly important in postmenopausal women, in that it may account in part for the higher prevalence of DED in older women. Other risk factors include environmental stressors such as contact lens wear, wind, pollution, and low humidity; corneal surgery such as LASIK (laser-assisted in situ keratomileusis); autoimmune conditions such as Sjögren syndrome; and the use of some medications. Among the medications that can increase the risk of DED are antihypertensives, anticholinergics, antihistamines, and antidepressants. Concurrent ocular conditions, such as meibomian gland dysfunction (MGD)⁶ and blepharitis,⁷ can also predispose to DED.

Table 1. Risk Factors for Dry Eye⁵

Level of Evidence		
Mostly Consistent*	Suggestive†	Unclear‡
Older age	Asian race	Cigarette smoking
Female sex	Medications	Hispanic ethnicity
Postmenopausal estrogen therapy	Tricyclic antidepressants	
Omega-3 and Omega-6 fatty acids imbalance	Selective serotonin reuptake inhibitors	Anti-cholinergics
Medications	Diuretics	Anxiolytics
Antihistamines	Beta-blockers	Antipsychotics
Connective tissue disease	Diabetes mellitus	Alcohol
LASIK and refractive excimer laser surgery	HIV/HTLV1 infection	Menopause
Radiation therapy	Systemic chemotherapy	Botulinum toxin injection
Hematopoietic stem cell transplantation	Large incision ECCE and penetrating keratoplasty	
	Isotretinoin	Acne
Vitamin A deficiency	Low humidity environments	Gout
Hepatitis C infection	Sarcoidosis	Oral contraceptives
Androgen deficiency	Ovarian dysfunction	Pregnancy

* Mostly consistent evidence implies the existence of at least 1 adequately powered and otherwise well-conducted study published in a peer-reviewed journal, along with the existence of a plausible biological rationale and corroborating basic research or clinical data

† Suggestive evidence implies the existence of either: 1) inconclusive information from peer-reviewed publications or 2) inconclusive or limited information to support the association, but either not published or published somewhere other than in a peer-reviewed journal

‡ Unclear evidence implies either directly conflicting information in peer-reviewed publications, or inconclusive information but with some basis for a biological rationale

Abbreviations: ECCE, extracapsular cataract extraction; HIV/HTLV1, human immunodeficiency virus/human T-cell lymphotropic virus type 1; LASIK, laser-assisted in situ keratomileusis.

Reprinted from *The Ocular Surface*, 5, Epidemiology Subcommittee of the International Dry Eye WorkShop, The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007), 93-107, Copyright 2007, with permission from Elsevier.

Dr Beckman: Historically, DED has been considered to be largely a disease of older women. How has the face of DED changed over time?

Dr McDonald: In my experience, more and more younger people—even college students—are presenting with DED. This is likely related to their use of smart devices—from computer screens to tablets to phones. A recent meta-analysis found that 50% of working-aged people whose job necessitates use of video display terminals report symptoms of DED.⁸

Dr Beckman: I have seen this trend as well. Young people are spending more time staring at screens, which reduces blink rate and predisposes to DED. Other contributing factors in this age group include long study sessions, staying up late, drinking coffee, and contact lens overwear. Together, these factors stress the ocular surface and increase the risk of triggering DED.

Dr O'Brien: While women are statistically more likely than men to be affected by DED, the gender gap is closing, especially among younger patients, in that working men and women may be equally affected in terms of reading speed and lowered productivity in the workplace. In addition to the personal suffering, this loss of productivity exerts considerable economic costs and a significant financial burden.

Update on Pathophysiology of Dry Eye Disease —Mark S. Milner, MD, FACS

Over the past 20 years, our understanding of DED has changed in 4 important ways. First, we know now that DED is an inflammatory process. In both animal models⁹ and human DED,¹⁰ the lacrimal gland and the conjunctiva are infiltrated with T-lymphocytes. Second, DED is no longer considered a static condition, but may be a chronic, progressive disease¹¹ that can ultimately lead to damage to the ocular surface. Third, we have therapies today that go beyond supportive care to treat the underlying causes of DED.¹¹ And fourth, we now view DED as not just an abnormal *quantity* of tears, but also as an abnormal *quality* to the tear film.

Any of the 3 layers of the tear film—the lipid layer arising from the meibomian glands, the aqueous layer from the lacrimal and accessory lacrimal glands, or the mucin layer from the conjunctival goblet cells—can become impaired and lead to DED. Together, these 3 layers form an aqueous mucin gel, a complex mixture of proteins, mucin, and electrolytes. The proteins include antimicrobial factors such as lysozyme and lactoferrin, as well as growth factors, inflammation suppression factors, and immunoglobulins. Mucins such as the soluble 5AC mucins provide viscosity to tears, and electrolytes ensure the proper osmosis for optimal tear function.¹²

In the dry eye, this balance of tear components is detrimentally altered.¹³⁻¹⁵ Altered cytokine levels may promote inflammation while reduced growth factor levels and protease activation may impair the healing processes of the ocular surface. Loss of goblet cells will reduce levels of soluble mucin 5AC to adversely affect tear viscosity, whereas increased concentrations of electrolytes will raise tear osmolarity and promote desiccation and death of ocular surface cells. Ocular surface damage then becomes cyclical (**Figure 1**)¹⁶: desiccation stresses the ocular surface and concentrates the tear film, which increases osmolarity and leads to release of cytokines such as interleukin-6, tumor necrosis factor alpha, interleukin-1, and matrix metalloproteinases (MMPs) that can further promote cell damage and hyperosmolarity. These inflammatory factors activate antigen-presenting cells, which migrate into the lymphatic system and recruit T-lymphocytes to the ocular surface, promoting further cytokine release and propagation of the inflammatory response.




Figure 1. Cyclical nature of ocular surface inflammation in dry eye disease

Abbreviations: APC, antigen-presenting cell; CAM, cell-adhesion molecule; iAPC, immature antigen-presenting cell; IFN, interferon; IL, interleukin; mAPC, mature antigen-presenting cell; MMP, matrix metalloproteinase; TGF, transforming growth factor; Th, T helper; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.

Reproduced with permission from *Archives of Ophthalmology*, 2012. 130(1): 90-100. Copyright © 2012 American Medical Association. All rights reserved.

If left uninterrupted, this cyclic process can lead to worsening DED and, consequently, ocular surface damage. As we understand the inflammatory nature of DED, our treatments have evolved from supportive therapies such as artificial tears to more targeted therapies such as cyclosporine A and lifitegrast, both of which inhibit T-lymphocyte activation through different mechanisms with the common goal of breaking the inflammatory cycle.

What triggers the inflammatory cycle that leads to DED? The risk factors associated with DED have been illustrated above. The interaction of these risk factors and the various mechanisms that contribute to the inflammatory cycle in DED is illustrated in **Figure 2**.




Figure 2. A schematic diagram depicting the interaction and cycle of disease triggers and the various mechanisms of DED

Dr Beckman: How has our appreciation for the inflammatory basis of DED changed our approach to patients with this disease?

Dr O'Brien: There was a time when “dry eye” was just that, and *inflammation* was the “Emperor’s New Clothes” —

something we anticipated with great fanfare, but often that which we could not readily identify by conventional examination. Inflammation is no longer a fairy tale in DED, but rather the rule, not the exception. This fundamental awareness has totally changed our entire approach to both diagnosis and therapy.

Dr Matossian: I find it helpful to educate patients on the inflammatory nature of DED. I tell them this is a chronic disease with many different contributing factors. I reinforce to my patients that we are not going to make it better overnight, nor will we be able to cure it. Knowing this helps our patients better understand why the treatment course will be chronic and, potentially, even lifelong.

Dr Beckman: Are there systemic ramifications to inflammation in patients with DED?

Dr McDonald: Many of our patients with DED have other systemic issues that need to be addressed. One example is the perimenopausal woman who presents with DED. She often does not make the connection that her DED is arising in part because of her changing hormone profile. These patients can often benefit from consultation with their gynecologist or an endocrinologist. Our patients with DED associated with Sjögren syndrome clearly have systemic inflammation that can manifest with oral issues such as gum recession, cavities, and halitosis. These were issues we did not consider when we viewed DED as a disease of senescence rather than one of inflammation.

Dr Beckman: As we have become more aware of the inflammatory nature of DED, what effect has it had on our therapeutic approach to the disease?

Dr Wu: Years ago, the first steps in the treatment of mild-to-moderate DED were artificial tear supplementation and punctal plugs. I currently initiate anti-inflammatory therapy much earlier in the clinical management of DED. Also, I use punctal plugs less often, and not as early in the clinical course as I used to.

Table 2. Conditions That Can Mimic Dry Eye Disease¹⁷

Superior limbic keratoconjunctivitis
Medicamentosa (topical medication toxicity)
Superficial punctate keratitis of Thygeson
Mucus fishing syndrome
Contact lens-related toxicity
Chemical toxicity (eg, hairspray toxicity)
Allergic/Atopic conjunctivitis
Conjunctivochalasis
Floppy lid syndrome
Lagophthalmos, with subsequent exposure keratitis

Dr Milner: A number of unrelated conditions can mimic DED and should be considered when the presentation is atypical for DED or is recalcitrant to DED therapies (Table 2).¹⁷ Diagnostic testing can aid in determining which of these types of DED we are dealing with in each individual patient.

New Diagnostic Tools

—Marguerite B. McDonald, MD, FACS

Diagnostic testing for DED focuses on identifying the damage, or the factors causing the damage, arising from the known pathophysiology of the disease. Testing can also identify the underlying factors contributing to DED in each individual patient. There are many tests, each of which provides additive information to help piece together the complex pathophysiology of the disease on a patient-by-patient basis.

Osmolarity. One key aspect of DED pathophysiology is tear film hyperosmolarity. This is the central pathophysiologic mechanism for all forms of DED. Hyperosmolarity causes inflammation and apoptosis of ocular surface cells; this leads to a breakdown of homeostatic control, causing tear film instability, and reduces the ability of mucins to lubricate the ocular surface.¹⁸

Tear film hyperosmolarity is a global marker of DED, indicating a concentrated tear film. Hyperosmolarity has been added to the definition of DED,¹⁸ and when above 316 mOsm/L, has been shown to have a higher predictive value for diagnosing DED than Schirmer, lactoferrin assay, or rose bengal staining.¹⁹

As a result of studies in the peer-reviewed literature, dry eyes are said to have either a higher than normal (300 mOsm/L) tear osmolarity or a difference between the 2 eyes of greater than 8 mOsm/L.^{20,21} What accounts for this? Healthy eyes have great reserve; the osmolarity does not change, even when the patient is confronted with the many challenges and conditions of modern life. They can take an oral decongestant, drink a glass or 2 of wine, sit outside for hours at a windy football game, work on their computers all day in offices with forced air heating and cooling, and their osmolarity readings are stable and virtually identical in both eyes. Dry eyes have little or no reserve. When confronted with these situations, they decompensate immediately. Their already elevated osmolarity swings wildly, up and down; the 2 eyes no longer have stable and virtually identical osmolarity scores that are within the normal range. That is why dry eye manifests itself with either a higher than normal (300 mOsm/L) tear osmolarity or a difference between the 2 eyes of greater than 8 mOsm/L.

Tear film osmolarity can be easily and noninvasively measured in the office. The only system available for commercial use, TearLab, is a nanofluidics platform using electrochemical detection methodology. The sample volume is 50 nL, the sampling time is 1 second, and results are available in 10 seconds after the handpiece is docked in its station. The device's manufacturer conducted a study demonstrating that a cutoff value of 308 mOsm/L provided 88% specificity and 75% sensitivity in detecting mild-to-moderate DED and 95% sensitivity in detecting severe DED.²²

MMP-9. Matrix metalloproteinases are proteolytic enzymes that are produced by stressed epithelial cells on the ocular surface. Of these, MMP-9 is a nonspecific inflammatory marker. The concentration of MMP-9 in tears becomes elevated in DED. MMP-9 levels correlate with clinical examination findings.²³

Tear MMP-9 levels can also be measured in the clinic setting using the InflammDry handheld testing device. The test can be administered by a technician or nurse, and results are available within 10 minutes. Several studies have demonstrated the clinical use of this point-of-care test.^{24,25}

Lactoferrin. Lactoferrin is a glycoprotein secreted by the lacrimal gland that plays an important role in regulating ocular surface cell growth, and because it is bacteriostatic, defends against infections.²⁶ Low tear lactoferrin levels can be a sign of lacrimal gland dysfunction, particularly in those with DED related to Sjögren syndrome.²⁷

Conjunctival cell impression cytology. Sampling conjunctival cells for biomarkers of inflammation is a relatively invasive procedure. A new device—EYEPRIM—produces RNA samples comparable to those obtained with traditional impression cytology that are adequate for analysis of inflammatory biomarkers,²⁸ without the need for topical anesthesia.

Serum biomarkers. Novel early biomarkers for Sjögren syndrome have been identified, including salivary protein-1 (SP-1), carbonic anhydrase (CA-6), and parotid secretory protein (P-SP).²⁹ These biomarkers are expressed earlier in the disease and have higher sensitivity and specificity than the more traditional biomarkers Ro or La. With earlier detection, there is a better opportunity to prevent complications of Sjögren, such as xerostomia, pulmonary fibrosis, and non-Hodgkin lymphoma.

Lipid layer interferometry. Commercial systems can now provide quantitative and qualitative measures of lipid layer thickness (LLT). The LipiView instrument has documented that LLT values ≤ 60 nm yield a 90% specificity for MGD.³⁰

The Keratograph 5M also uses interferometry to measure the thickness of the lipid layer of the tear film³¹ using an observable field of 9 mm.

Meibomography. The LipiView, LipiScan, and the Keratograph 5M devices also provide meibomography to visualize gland architecture and reveal pathology such as duct dilation, gland constipation, atrophy, and dropout^{32,33} (**Figure 3**).




Figure 3. Meibomography with the LipiScan instrument. Early (left), moderate (center), and severe (right) meibomian gland dysfunction. Note the progressive loss of ducts as the disease worsens.

Image Courtesy of Marguerite B. McDonald, MD, FACS

Tear volume. Optical coherence tomography can measure several aspects of tear quantification, including tear meniscus height (TMH), area and volume, as well as the true precorneal tear film thickness. Low TMH values can provide sensitivity of 92% and specificity of 90% for the detection of DED,³⁴ and values correlate strongly with symptoms.³⁵

Tear break-up time (TBUT). Tear break-up time has long been an important metric in the evaluation of DED. An automated measure of noninvasive keratography break-up time (NIKBUT) is now available with the Keratograph 5M.³³

The result of all the DED tests performed by the Keratograph 5M can be aggregated into the JENVIS Dry Eye Report (**Figure 4**). In this graphical representation of testing data, the shape of the blue hexagon indicates the nature of DED responsible for each individual patient's ocular surface status. These tests include the automated NIKBUT, meibography, the Dry Eye Ocular Surface Disease Index questionnaire, tear meniscus height, LIPCOF (lid parallel conjunctival folds) score, and ocular redness and limbal redness (ciliary flush) scores. The Keratograph 5M also has a Placido-based topographer and the OxiMap for visualizing oxygen permeability, so that a patient with dry eye can be fit with the contact lens that allows for the best oxygen supply to the cornea.³³

Dr Beckman: With so many new tests to complement our standard tests of the ocular surface—including Schirmer, dye staining, and manual TBUT—what is the optimal workup for a patient with dry eye today?

Dr Matossian: It would be great to perform a full battery of all these tests to more accurately characterize our patients with dry eye, but that is impractical and often unnecessary.




Figure 4. The JENVIS Dry Eye Report summarizing all DED testing from the Keratograph 5M. Values are depicted in green (normal), yellow (borderline), or red (abnormal) zones.

Image Courtesy of Marguerite B. McDonald, MD, FACS

I generally start with a few tests, and the results of these—coupled with the patient's specific history—will guide my further workup. First is tear osmolarity and MMP-9 testing; second is lissamine green staining. I look at the staining pattern of the lid margin and conjunctiva as well as the cornea. Third is meibomography, wherein I focus on the extent of dropout.

Dr Wu: I perform TBUT at the slit lamp after assessing staining patterns. Then I express the meibomian glands with a cotton-tipped applicator to qualitatively assess the consistency of the secretions. If the meibomian gland status appears abnormal, I will obtain meibomography. I do not often do Schirmer testing unless I suspect Sjögren syndrome or autoimmune disease.

Dr McDonald: I agree. I usually perform Schirmer testing only to document epiphora before referring patients to the oculoplastics service or if a study protocol requires it. I do not use it routinely to diagnose dry eye.

Dr Matossian: I have stopped using the Schirmer test routinely.

Dr Beckman: I typically do Schirmer testing once early in the care process to estimate aqueous production. It may help guide my decision to use punctal plugs if I see a low Schirmer result. Otherwise I do not use it routinely.

Dr Milner: I seem to be in the minority of people who still use Schirmer testing routinely. I tend to treat dry eye more according to its underlying cause than its severity. I find that the Schirmer test without anesthesia can be very helpful in distinguishing between aqueous deficiency and evaporative loss as the underlying cause of DED.

Dr Luchs: One of the most important pieces of data that I consider when evaluating dry eye is the patient's clinical history. I have instructed my staff regarding how to take the

history, including soliciting symptoms of DED. Too many of our patients fail to report the classic symptoms—fluctuating vision and sensations of dryness, grittiness, stinging, burning—because they assume those sensations are a normal part of aging. As for diagnostic tests, I test osmolarity routinely. The test is quick and easy to perform.

Dr O'Brien: It is always important to listen to our patients. In DED, moreover, we have to remain aware of the well-documented disconnect between symptoms and signs.^{36,37} Validated questionnaires can assist with uncovering symptoms and assessing their severity. As for the examination, I think that a minimum evaluation should include measurement of TBUT with fluorescein to assess tear film instability, grading the severity of ocular surface cellular damage using lissamine green or fluorescein staining, as well as an assessment of tear volume/production with Schirmer testing (I prefer Schirmer I) or anterior segment optical coherence tomography. This information can help classify the DED as aqueous deficient or evaporative, grade severity, and guide management.

Dr McDonald: For the comprehensive ophthalmologist reading this and considering the wide array of tests available, I recommend a simple approach. Start with a good history, then tear osmolarity, because hyperosmolarity is the central pathway by which all ocular surface damage occurs in DED. Testing for osmolarity must be performed early in the examination, before the ocular surface is disturbed. I usually assess MMP-9 at this point as well, especially if the patient has complaints that suggest dry eye, but his or her osmolarity is normal. Then I assess staining with both lissamine and fluorescein. These tests are easy to administer, inexpensive, and will identify most patients with DED. The next level of evaluation would be meibomography to assess the status of the meibomian glands and to look for dropout.

Dr Matossian: I find MMP-9 testing helpful. When the result is positive, I tend to treat more aggressively than if it was negative. One word of caution when introducing tear osmolarity testing into your practice: Staff training is critically important; so is equipment calibration. MMP-9 testing is easy to perform once technicians are trained. Interpretation of the tear osmolarity data can be confusing initially, considering osmolarity fluctuates in hyperosmolar patients. I find trends over time are more informative than isolated readings.

New Treatment Options

—Jodi Luchs, MD

Not so long ago, we considered DED to be a disease primarily of decreased tear production, and our therapies—artificial tears and punctal plugs—aimed to replace or enhance the volume of existing tears. We did not fully appreciate the significance of inflammation in the DED disease process. We tended to reserve anti-inflammatory

drugs such as topical steroids for patients with more severe disease. In retrospect, the patients with more severe disease likely would have benefitted from anti-inflammatory therapy much earlier in their disease course. The damage they have suffered to their lacrimal gland and to their ocular surface may have been preventable had the inflammatory cycle been broken earlier in the clinical course.¹¹

We know now that DED is not simply a condition of the tear film in isolation, but that it has a complex pathophysiology that offers several potential therapeutic targets and presents in several clinical scenarios. Our goals in therapy are to identify the underlying causes of dry eye in each of our patients and to select therapies that target those specific causes.

Cyclosporine A was FDA approved for the treatment of DED 15 years ago. It is indicated to increase tear production in patients whose tear production is presumed to be suppressed because of ocular inflammation associated with keratoconjunctivitis sicca. Clinical trials have demonstrated increased tear production, reduced corneal staining, reduced use of artificial tears, and increased goblet cell density after 6 months of therapy.^{38,39} Cyclosporine A forms a complex with cyclophilin that inhibits the phosphatase activity of calcineurin.¹⁶ This decreases cytokine production and T-cell migration into the tissues of the ocular surface.

In 2016, lifitegrast was FDA approved for DED. This new drug is indicated for the treatment of the signs and symptoms of DED. Three phase 3 clinical trials have been conducted. Improvement in symptoms of eye dryness was noted after 6 weeks of therapy in all 3 studies and after 2 weeks in 2 of the studies⁴⁰ (**Figure 5**). In 2 of the 3 studies, improvement in inferior corneal staining was demonstrated after 3 months of therapy.⁴⁰⁻⁴² The most common adverse event associated with lifitegrast in all 3 studies was discomfort upon instillation. Lifitegrast is an antagonist of lymphocyte function-associated antigen 1 (LFA-1).⁴³ It prevents binding of LFA-1 to key cell surface receptors, thereby blocking T-cell activation, adhesion, migration, and cytokine release.




Figure 5. Change from baseline to day 84 in symptom scores in the placebo and lifitegrast groups in OPUS-2. Eye dryness score (EDS) was a coprimary end point.⁴⁰ Abbreviations: LOCF, last observation carried forward; SE, standard error.

Also in 2016, cyclosporine A was approved in a multidose package while remaining preservative free,⁴⁴ thus providing increased convenience for patients who might otherwise struggle with the single-dose vials in which cyclosporine A had been previously supplied.

Several new therapies for DED are on the near horizon. One is a novel nanomicellar formulation of cyclosporine A at a 0.09% concentration that was shown in clinical trials to provide improvement in Schirmer scores in as little as 12 weeks.⁴⁵

A novel nonpharmacologic therapy, the TrueTear nasal neurostimulatory device, was recently granted marketing authorization by the FDA.⁴⁶ This treatment stimulates production of the aqueous, mucin, and lipid components of the tear film. According to the recent press release, in 2 clinical trials, the primary effectiveness end point of increased tear production measured by Schirmer score was met.⁴⁶ There were no serious device-related adverse events reported. The most common nonserious device-related adverse events recorded in the trials were nasal pain, discomfort, or burning (10.3%), transient electrical discomfort (5.2%), and nosebleed (5.2%).⁴⁶ Symptom scores and corneal and conjunctival staining were measured in another study in 34 patients who used a prototype of the nasal neurostimulatory device. In that open label non-randomized study, scores from baseline to day 180 were significantly reduced in patients with mild-to-severe DED.⁴⁷ This nasal neurostimulatory device might be a reasonable complement to topical pharmacologic therapy.

CASE DISCUSSIONS

CASE 1. Dry Eye Disease and Eye Pain Following Refractive Surgery

—From the Files of Helen K. Wu, MD

A 45-year-old man underwent photorefractive keratectomy (PRK) in 2011 for hyperopia in both eyes. He experienced prolonged pain in both eyes after the procedure. His postoperative uncorrected visual acuity was 20/25 in the right eye and 20/50 in the left; best corrected visual acuity (BCVA) in the left eye was also diminished to 20/30. Slit-lamp examination revealed mild subepithelial haze typical of post-PRK appearance in both eyes, with slightly diminished tear lakes and decreased TBUT in both eyes. There was also mild irregular astigmatism in the left eye.

He was initially treated with lubricants, topical cyclosporine, and topical steroids for several weeks, as well as oral omega-3 supplements for several months. Punctal plugs were placed 6 to 8 weeks after initiating topical anti-inflammatory therapy. Despite these interventions, his pain persisted in both eyes, and the visual acuity remained diminished in the left eye. We attempted rigid gas permeable contact lens fitting, but

he was unable to tolerate the lenses because of pain. He was then lost to follow-up for 5 years when he presented with persistent pain in both eyes. His examination was essentially unchanged, with mild dry eye noted. There was no evidence of anterior basement membrane dystrophy, and his ocular pain was mostly—but not completely—improved with topical anesthesia.

At this point we performed confocal microscopy (Figure 6), which demonstrated decreased density and




Figure 6. Confocal microscopy of the corneas of the patient presented in Case 1. Top 4 images, right eye; bottom 4 images, left eye. Abnormal nerve regeneration after photorefractive keratectomy in both eyes, with increased neuromas noted in the left eye.

Images Courtesy of Helen K. Wu, MD

increased tortuosity of the nerves in both eyes and neuromas in the left cornea. We continued the current therapies, consisting of topical steroids, cyclosporine, lubricants, and plugs. I added lifitegrast twice daily to both eyes as well as serum tears every 2 hours. He was also fitted for a prosthetic replacement of the ocular surface ecosystem (PROSE) device. This patient has been lost to follow-up since.

Dr Beckman: What are the hallmarks of corneal neuropathic pain?

Dr Wu: Injured neurons may develop after refractive surgery. The terminals of these injured neurons swell, forming what are called endobulbs. Small neuromas form here as the neuron tries unsuccessfully to regenerate itself. These injured nerves can cause classic neuropathic pain, which is characterized by a triad of symptoms: hyperalgesia, allodynia, and spontaneous pain. Allodynia is the sensation of severe pain resulting from seemingly innocuous stimuli such as bright lights or light touch. In the cornea, neuropathic pain might be perceived as irritation, itching, burning, aching, light sensitivity, or grittiness.⁴⁸

Dr Beckman: What clinical features might suggest this diagnosis?

Dr Wu: In these cases, regrettably, standard dry eye testing may be normal. The patient did have diminished TBUT, but normal Schirmer scores. The proparacaine challenge test was informative in that instillation of proparacaine did not completely relieve his symptoms. The gold standard for diagnosis is laser in vivo confocal microscopy.

Dr Beckman: Why do you think the decreased nerve density is associated with the increased pain? We typically think of the nerve loss with laser surgery leading to a desensitized cornea.

Dr Wu: I think what happened is that the peripheral corneal nerves were affected in this case by the PRK. This causes structural changes in the nerves, leading to sensitization of the nerve fibers. These changes are not limited to the peripheral nervous system—they can spread to the central nervous system as well, in which case patients may require systemic pharmacotherapy with agents such as nortriptyline, naltrexone, or even opioids. Some patients turn to acupuncture and other alternative treatments. The point is that such patients can be very difficult to treat.

Dr McDonald: This patient had hyperopic PRK, so he had a large diameter ablation in both eyes that may have damaged the trunk nerves coming in at 3 and at 9 o'clock. A central PRK for myopia damages far fewer of the nerves.

Dr Beckman: Can you address your decision to add lifitegrast to cyclosporine?

Dr Wu: If the patient has a partial response to cyclosporine, I will continue it and add lifitegrast.

Dr Matossian: I also have patients on both agents, and I proceed just as Dr Wu described, adding lifitegrast in patients who show incomplete resolution of symptoms on cyclosporine alone. Each of these 2 T-cell inhibitors work differently. It makes sense to interrupt the inflammatory process at 2 different points along the pathway.

Dr Milner: We all have patients who report definite improvement with cyclosporine or lifitegrast alone, but may still have symptoms, and I too add the other, lifitegrast or cyclosporine, to these patients' regimens. There are no head-to-head studies or additivity studies that show a synergistic effect of the 2 agents. In the absence of such data, it is reasonable to assume that they are additive on the basis of their distinct mechanisms of action on the T-lymphocyte. As are many other diseases, such as glaucoma, I believe that DED is a complex disease that often needs multiagent treatment. Therefore, if I have a patient on either cyclosporine or lifitegrast alone and signs and/or symptoms improve but are not resolved, I will often add the other.

Dr O'Brien: These cases can be among the most challenging to manage, and the role of adjunctive imaging with confocal microscopy to confirm the diagnosis is essential. I agree with Dr Wu's use of the autologous serum tears to try to provide the various nerve growth factors and other humoral substances not present in artificial tears that may accelerate recovery and ameliorate symptoms. Topical nerve growth factor has been suggested and used in other neurotrophic ocular conditions, but is expensive and unapproved, and the dose response is incompletely determined. The judicious off-label use of very dilute topical anesthetics as previously recommended with surface photoablative procedures can be considered and monitored very carefully. Finally, because of not only the local ocular pain, but also the concomitant *central* mechanisms mediating chronic pain, these cases should be referred and comanaged with a reliable expert in pain management.

CASE 2. Dry Eye Disease and Upcoming Cataract Surgery

—From the Files of Cynthia Matossian, MD, FACS, ABES

A 65-year-old woman was seen in consultation for cataract surgery. She was pseudophakic in the right eye and felt that her vision was getting worse in both eyes. Specifically, she reported that she had difficulty driving home from work at night. Her BCVA was 20/25—in the right eye and 20/60 in the left eye. Her external examination is shown in **Figure 7**.

The patient's external examination revealed foamy deposits on the lower lid margins, indicative of MGD. Also, she had




Figure 7. External photographs of the patient presented in Case 2. Note the foamy deposits on the lid margins of both eyes as well as loss of lashes bilaterally.

Images Courtesy of Cynthia Matossian, MD, EACS, ABES

diffuse lash loss in both eyes, so severe that she had lash extensions placed on her upper lids. On the basis of the examination findings, she underwent testing for DED. Her tear osmolarity was 346 and 330 mOsm/L in the right and left eye, respectively, and her MMP-9 was positive in both eyes. Lissamine green and fluorescein dyes revealed staining of the inferior cornea and conjunctiva in both eyes. Corneal topography demonstrated significant irregular astigmatism, and meibomography (**Figure 8**) revealed extensive gland dropout.




Figure 8. Meibomography of the left eye of a patient with meibomian gland dysfunction. Note the diffuse loss of glands throughout the lower lid.

Image Courtesy of Alice Epiroponos, MD

Dr Beckman: What is the significance of the foamy tears in this patient?

Dr Luchs: The finding is typical of MGD. There are abnormal lipids in the tear film, which are being acted upon by bacterial lipases and turned into soaps. This can cause significant discomfort for the patient.

Dr Beckman: This patient now wants cataract surgery in her second eye. What did you do to prepare her ocular surface for surgery?

Dr Matossian: Her primary problem is her lids. I started with lid hygiene, which included scrubs and a microwaveable-heated mask to help soften secretions. I also performed vectored thermal pulsation treatment using the LipiFlow system. I then prescribed high-quality oral omega-3 supplements as well as lifitegrast and loteprednol topical therapy. I postponed measurements for lens calculations until her ocular surface was in better shape because hyperosmolarity of the tear film can lead to incorrect lens calculation.⁴⁹

Dr O'Brien: The role of microbial colonization of the lids/lashes in the pathogenesis of MGD has been incompletely understood, yet as was mentioned, bacterial *lipases* play a role in the enzymatic saponification of meibum into free fatty acids and soaps. Thus, it is rational to reduce excessive microbial colonization of the lid margins. The use of lid-cleansing agents, including those containing hypochlorous acid or linalool, which have natural antimicrobial and anti-inflammatory effects, could be beneficial for such a patient. A preoperative pulse with systemic low-dose doxycycline or minocycline, not so much for antibacterial benefits, but for immunodulatory effects, could theoretically prove beneficial in reducing preoperative inflammation of the lid margins. Topical azithromycin, 1%, once daily has also demonstrated favorable effects on clinical symptoms and signs of MGD as well as on restoring the lipid properties of meibomian gland secretions toward normal.⁵⁰

Dr Beckman: One additional point—it appears she may have a little bit of lower lid laxity, and her staining pattern supports some component of exposure. These eyes may be at increased risk of corneal infections. In addition to everything you did for her, I would have also considered some antibiotic ointment at night, both to lubricate during sleep and also to reduce the infection risk.

Dr McDonald: I agree with Dr Beckman; lagophthalmos and the resultant exposure keratitis appear to be present on the basis of her staining pattern and lid laxity. Lagophthalmos/Exposure keratitis is one of the most overlooked diagnoses in ophthalmology, and can negatively affect both preoperative measurements and postoperative recovery because the already-lax lids are stretched even further by the speculum.

Dr Beckman: How did this case turn out?

Dr Matossian: Upon return, her symptoms and lid margin appearance improved, as did her topography. With her ocular surface as optimized as possible, we proceeded with calculations and her surgery went smoothly, with a satisfactory visual outcome.

CASE 3. Dry Eye Disease in a Young Patient —From the Files of Terrence P. O'Brien, MD

A 23-year-old Asian woman presented with the complaint that her eyes get really tired and her vision “jumps around”. She had excellent systemic health, with some environmental allergies. Her medications included oral contraceptives, nonprescription antihistamines for allergy, and what she described as computer eyedrops. She consumes large quantities of coffee, does not smoke, and spends much time looking at computer monitors. On examination, her BCVA is 20/15 in the right eye and 20/20 in the left, with moderate myopic corrections in both eyes. Her external examination is shown in **Figure 9**.




Figure 9. External examination of the patient presented in Case 3. Note the evidence of meibomian gland dysfunction, lid telangiectasia, and foamy tear film.

Image Courtesy of Terrence P. O'Brien, MD

Lissamine green revealed early staining of the conjunctiva more so than of the cornea. Her TBUT was 5 and 4 seconds in the right and left eye, respectively. Schirmer testing was 9 mm in both eyes. Her osmolarity was within normal limits, but her MMP-9 was positive in both eyes.

Dr Beckman: This case demonstrates the new face of DED that we are seeing in younger people. It seems that this patient might benefit from both pharmacologic as well as some behavioral interventions.

Dr O'Brien: Exactly right. We started with education so she would understand how her lifestyle and environment contributed to her symptoms. I asked her to take frequent breaks during screen time, cut back on her caffeine intake, eat a healthy diet supplemented with omega-3 essential fatty acids, and practice good lid hygiene, including both warm compresses and massage. We asked her to stop the frequent preservative-containing “computer drops” and rather to lubricate with preservative-free artificial tears during the day and to apply gel at night. I prescribed a 1-month pulse of loteprednol etabonate, 0.5%, with gradual taper and initiated

chronic anti-inflammatory therapy with topical lifitegrast, 5%, twice daily. Topical cyclosporine A, 0.05%, is also an approved immunomodulatory alternative for maintenance anti-inflammatory therapy with a long track record of effectiveness and safety in management of patients with DED. It is important to address inflammation, both acutely and for the longer term, in this younger patient with aspects of both evaporative and aqueous-deficient DED.

Dr McDonald: I would add that not getting adequate sleep is a behavior that can aggravate DED. Some of my worst patients with dry eye are shift workers who are getting as few as 3 or 4 hours of sleep per night. This is another opportunity for behavior modification.

Dr O'Brien: Sleep is a precious and sometimes underappreciated commodity in systemic and ocular health. In a recent study of sleep and mood disorders in women with DED, sleep quality was significantly worse in women with than without DED. Mood disorders of depression and anxiety were major contributory factors, especially in the younger DED group.⁵¹

Summary and Take-Home Points

In this monograph, we have provided a modern framework for understanding the pathophysiology of DED as an inflammatory disease. New and emerging diagnostics provide excellent tools for identifying patients with DED, and an expanding array of therapeutics ensures that our patients with DED can find relief from their DED symptoms. The following take-home points provide a summary of our discussion:

- DED and ocular surface disease are increasingly prevalent in our modern multiscreen world and can be triggered and aggravated by the conveniences of modern society, including forced air heating and systemic medications
- DED affects our patients' visual function and their quality of life, and can have significant detrimental effects on issues such as contact lens wear and preoperative lens calculations for cataract surgery
- DED is a complex, multifactorial disease driven by inflammation, is both chronic and progressive, and often requires a multipronged therapeutic approach
- Given the inflammatory nature of DED, anti-inflammatory therapy should be instituted early to help control the underlying processes contributing to symptoms
- Innovative, new point-of-care testing can help us make the diagnosis of DED earlier in its course, before significant damage has been done to the ocular surface
- New and emerging therapeutics give us the most diverse array of treatment options to improve the health and quality of life of our patients with DED

References

1. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. *Am J Ophthalmol.* 2003;136(2):318-326.
2. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. *Arch Ophthalmol.* 2009;127(6):763-768.
3. Schein OD, Muñoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. *Am J Ophthalmol.* 1997;124(6):723-728.
4. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. *Arch Ophthalmol.* 2000;118(9):1264-1268.
5. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye Workshop (2007). *Ocul Surf.* 2007;5(2):93-107.
6. Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on Meibomian Gland Dysfunction: Executive Summary. *Invest Ophthalmol Vis Sci.* 2011;52(4):1922-1929.
7. Rynerson JM, Perry HD. DEBS – a unification theory for dry eye and blepharitis. *Clin Ophthalmol.* 2016;10:2455-2467.
8. Courtin R, Pereira B, Naughton G, et al. Prevalence of dry eye disease in visual display terminal workers: a systematic review and meta-analysis. *BMJ Open.* 2016;6(1):e009675.
9. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. *Cornea.* 1998;17(6):584-589.
10. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. *Invest Ophthalmol Vis Sci.* 2002;43(8):2609-2614.
11. Rao SN. Topical cyclosporine 0.05% for the prevention of dry eye disease progression. *J Ocul Pharmacol Ther.* 2010;26(2):157-164.
12. Stern ME, Beuerman RW, Pflugfelder SC. The normal tear film and ocular surface. In: Pflugfelder S, Beuerman R, Stern ME, eds. *Dry Eye and Ocular Surface Disorders.* Boca Raton, FL: CRC Press; 2004:41-62.
13. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. *Invest Ophthalmol Vis Sci.* 2001;42(10):2283-2292.
14. Zhao H, Jumblatt JE, Wood TO, Jumblatt MM. Quantification of MUC5AC protein in human tears. *Cornea.* 2001;20(8):873-877.
15. Ogasawara K, Mitsubayashi K, Tsuru T, Karube I. Electrical conductivity of tear fluid in healthy persons and keratoconjunctivitis sicca patients measured by a flexible conductimetric sensor. *Graefes Arch Clin Exp Ophthalmol.* 1996;234(9):542-546.
16. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. *Arch Ophthalmol.* 2012;130(1):90-100.
17. Milner MS, Beckman KA, Luchs JJ, et al. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment. *Curr Opin Ophthalmol.* 2017;27(suppl 1):3-47.
18. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). *Ocul Surf.* 2007;5(2):75-92.
19. Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film osmolarity: determination of a referent for dry eye diagnosis. *Invest Ophthalmol Vis Sci.* 2006;47(10):4309-4315.
20. Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. *Invest Ophthalmol Vis Sci.* 2010;51(12):6125-6130.
21. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. *Am J Ophthalmol.* 2011;151(5):792-798.e1.
22. Foulks GN, Lemp MA, Berg MP, Bhola R, Sullivan B. TearLab™ osmolarity as a biomarker for disease severity in mild to moderate dry eye disease. Poster presented at: 2009 Annual Meeting of the American Academy of Ophthalmology; October 24-27, 2009; San Francisco, CA. Poster P0382.
23. Chotikavanich S, de Paiva CS, Li de Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. *Invest Ophthalmol Vis Sci.* 2009;50(7):3203-3209.
24. Messmer EM, von Lindenfels V, Garbe A, Kampik A. Matrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay. *Ophthalmology.* 2016;123(11):2300-2308.
25. Sambursky R, Davitt WF 3rd, Friedberg M, Tauber S. Prospective, multicenter, clinical evaluation of point-of-care matrix metalloproteinase-9 test for confirming dry eye disease. *Cornea.* 2014;33(8):812-818.
26. Flanagan JL, Willcox MD. Role of lactoferrin in the tear film. *Biochimie.* 2009;91(1):35-43.
27. Ohashi Y, Ishida R, Kojima T, et al. Abnormal protein profiles in tears with dry eye syndrome. *Am J Ophthalmol.* 2003;136(2):291-299.
28. López-Miguel A, Gutiérrez-Gutiérrez S, García-Vázquez C, Enríquez-de-Salamanca A. RNA collection from human conjunctival epithelial cells obtained with a new device for impression cytology. *Cornea.* 2017;36(1):59-63.
29. Shen L, Suresh L, Lindemann M, et al. Novel autoantibodies in Sjögren's syndrome. *Clin Immunol.* 2012;145(3):251-255.
30. Finis D, Pischel N, Schrader S, Geerling G. Evaluation of lipid layer thickness measurement of the tear film as a diagnostic tool for meibomian gland dysfunction. *Cornea.* 2013;32(12):1549-1553.
31. Ji YW, Lee J, Lee H, Seo KY, Kim EK, Kim TI. Automated measurement of tear film dynamics and lipid layer thickness for assessment of non-Sjögren dry eye syndrome with meibomian gland dysfunction. *Cornea.* 2017;36(2):176-182.
32. TearScience. A streamlined method for evaluating the meibomian glands. Tear Science Web site. <https://tearscience.com/en/the-tearscience-system/diagnosis/>. Accessed May 12, 2017.
33. OCULUS, Inc. The OCULUS Keratograph® 5M. OCULUS Web site. <http://www.oculus.de/us/products/topography/keratograph-5m/highlights/>. Accessed May 12, 2017.
34. Shen M, Li J, Wang J, et al. Upper and lower tear menisci in the diagnosis of dry eye. *Invest Ophthalmol Vis Sci.* 2009;50(6):2722-2726.
35. Veres A, Tapasztó B, Kosina-Hagyó K, Somfai GM, Németh J. Imaging lid-parallel conjunctival folds with OCT and comparing its grading with the slit lamp classification in dry eye patients and normal subjects. *Invest Ophthalmol Vis Sci.* 2011;52(6):2945-2951.
36. Sullivan BD, Crews LA, Messmer EM, et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. *Acta Ophthalmol.* 2014;92(2):161-166.
37. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. *Cornea.* 2004;23(8):762-770.
38. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. *Ophthalmology.* 2000;107(4):631-639.
39. Yüksel B, Bozdağ B, Acar M, Topaloğlu E. Evaluation of the effect of topical cyclosporine A with impression cytology in dry eye patients. *Eur J Ophthalmol.* 2010;20(4):675-679.
40. Tauber J, Karpecki P, Latkany R, et al; OPUS-2 Investigators. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. *Ophthalmology.* 2015;122(12):2423-2431.
41. Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3). *Ophthalmology.* 2017;124(1):53-60.
42. Sheppard JD, Torkildsen GL, Lonsdale JD, et al; OPUS-1 Study Group. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. *Ophthalmology.* 2014;121(2):475-483.
43. Perez VL, Pflugfelder SC, Zhang S, Shojaei A, Haque R. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. *Ocul Surf.* 2016;14(2):207-215.
44. Allergan introduces RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%, a new delivery system for the one and only FDA approved treatment to help patients produce more of their own tears. October 28, 2016. Allergan Web site. <http://www.allergan.com/INVESTORS/News/Thomson-Reuters/Allergan-Introduces-RESTASIS-MULTIDOSE-Cyclospori>. Accessed February 19, 2017.
45. Sun Pharma announces positive topline results of confirmatory phase-3 clinical trial or Seciera™ for treatment of dry eye [news release]. Mumbai, India: Sun Pharmaceutical Industries Ltd; January 4, 2017. <http://www.sunpharma.com/Media/Press-Releases/Press%20Release%20Sun%20Pharma%20Announces%20Positive%20Results%20of%20Confirmatory%20Phase-3%20Clinical%20Trial%20for%20Seciera-.pdf>. Accessed February 19, 2017.
46. Allergan granted marketing authorization by the FDA for TrueTear™, the first intranasal neurostimulating device proven to temporarily increase tear production [press release]. Dublin, Ireland: PRNewswire; April 25, 2017.
47. Friedman NJ, Butron K, Robledo N, Loudin J, Baba SN, Chayet A. A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease. *Clin Ophthalmol.* 2016;10:795-804.
48. Goyal S, Hamrah P. Understanding neuropathic corneal pain—gaps and current therapeutic approaches. *Semin Ophthalmol.* 2016;31(1-2):59-70.
49. Epiropoulos AT, Matossian C, Berdy GJ, Malhotra RP, Potvin R. Effect of tear osmolarity on repeatability of keratometry for cataract surgery planning. *J Cataract Refract Surg.* 2015;41(8):1672-1677.
50. Foulks GN, Borchman D, Yappert M, Kim SH, McKay JW. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. *Cornea.* 2010;29(7):781-788.
51. Ayaki M, Kawashima M, Negishi K, Kishimoto T, Mimura M, Tsubota K. Sleep and mood disorders in women with dry eye disease. *Sci Rep.* 2016;6:35276.

CME Post Test Questions

To obtain *AMA PRA Category 1 Credit™* for this activity, complete the CME Post Test by writing the best answer to each question in the Answer Box located on the Activity Evaluation/Credit Request form on the following page. Alternatively, you can complete the CME Post Test online at <http://www.tinyurl.com/CurrentOpinionsDryEye>.

See detailed instructions at **To Obtain *AMA PRA Category 1 Credit™*** on page 2.

- Which of the following has high-level evidence for establishing it as a risk factor for DED?
 - Oral contraceptive use
 - Menopause
 - Radiation therapy
 - Use of a systemic beta-blocker
- The prevalence of DED in young adults is increasing. What is the likely cause of this observation?
 - Higher rates of teen smoking
 - Increased use of oral contraceptives
 - Increased time spent staring at video screens
 - Climate change
- When evaluating a patient with symptoms of DED, _____ is a condition that often mimics these symptoms.
 - Primary acquired melanosis
 - Conjunctivochalasis
 - Keratoconus
 - Dacryocystitis
- Which of the following is not a factor in the pathophysiology of DED?
 - Increased tear osmolarity, cytokine release, and inflammation
 - Allodynia
 - Recruitment of T lymphocytes to the ocular surface
 - Decrease in goblet cells
- Foamy tears on the lid margin are a sign of _____.
 - Corneal foreign body
 - Allodynia
 - Goblet cell loss
 - Meibomian gland dysfunction
- Which of the following tests can be helpful in diagnosing DED regardless of symptom severity?
 - MMP-9
 - TBUT
 - Meibomography
 - All the above
- While cyclosporine A and lifitegrast have distinct mechanisms of action, they both work by interfering with _____.
 - Evaporative tear loss
 - The calcineurin phosphatase pathway
 - T-lymphocyte activation and migration
 - LFA-1
- In clinical trials, symptoms of DED may show improvement in as early as _____ of therapy with lifitegrast.
 - 3 days
 - 2 weeks
 - 3 months
 - 6 months
- A 60-year-old woman is referred for dry eye that has not improved with artificial tears. She complains of foreign body sensation, irritation, fluctuating vision, and grittiness. Visual acuity is 20/60 OD and 20/60 OS. Her TBUT is 2 seconds OU, and there is no staining of the cornea or conjunctiva and no scarring. Schirmer testing is 19 mm OD and 21 mm OS. What additional test would be optimal to target treatment?
 - Nothing else needed to target treatment
 - Tear osmolarity
 - Sjögren titer
 - Meibomography
- A 45-year-old man, a stockbroker, wants LASIK. He has no relevant medical history, but spends a lot of time at work looking at computer and phone screens. His visual acuity is 20/40 OU; his tear film osmolarity is 321 mOsm/L OD and 331 mOsm/L OS; his TBUT is 4 seconds OD and 3 seconds OS. There is no corneal staining, but MMP-9 testing is positive OU. Which of the following treatments would be the most reasonable?
 - Artificial tears alone
 - Artificial tears plus an anti-inflammatory such as lifitegrast or cyclosporine
 - Punctal plugs
 - Amniotic membrane placement

VISIT [HTTP://WWW.TINYURL.COM/CURRENTOPINIONSDRYEYE](http://www.tinyurl.com/currentopinionsdryeye) FOR ONLINE TESTING AND INSTANT CME CERTIFICATE.

**Current Opinions and Modern Approaches
in the Diagnosis and Treatment of
DRY EYE DISEASE**